1 Koch, R. in Tenth International Congress of Medicine 1 (August Hirschwald, Berlin, 1891).

2 Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539–545 (2001).

3 Trinchieri, G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu. Rev. Immunol. 30, 677–706 (2012).

4 Moore, P. S. & Chang, Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nature Rev. Cancer 10, 878–889 (2010).

5 Virchow, R. in Die krankhaften Geschwülste (ed. Virchow, R.) 57–101 (Verlag von August von Hirschwald, Berlin, 1863).

6 Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883–899 (2010).

7 Turnbaugh, P. J. et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027–1031 (2006).

8 Smith, M. I. et al. Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science 339, 548–554 (2013).

9 O'Hara, A. M. & Shanahan, F. The gut flora as a forgotten organ. EMBO Rep. 7, 688–693 (2006).

10 Savage, D. C. Microbial ecology of the gastrointestinal tract. Annu. Rev. Microbiol. 31, 107–133 (1977).

11 Gill, S. R. et al. Metagenomic analysis of the human distal gut microbiome. Science 312, 1355–1359 (2006).

12 Kau, A. L., Ahern, P. P., Griffin, N. W., Goodman, A. L. & Gordon, J. I. Human nutrition, the gut microbiome and the immune system. Nature 474, 327–336 (2011).

13 Fraher, M. H., O'Toole, P. W. & Quigley, E. M. Techniques used to characterize the gut microbiota: a guide for the clinician. Nature Rev. Gastroenterol. Hepatol 9, 312–322 (2012).

14 Consortium, H. M. P. Structure, function and diversity of the healthy human microbiome. Nature 486, 207–214 (2012).

15 Colditz, G. A., Sellers, T. A. & Trapido, E. Epidemiology — identifying the causes and preventability of cancer? Nature Rev. Cancer 6, 75–83 (2006).

16 Peto, J. Cancer epidemiology in the last century and the next decade. Nature 411, 390–395 (2001).

17 Grice, E. A. & Segre, J. A. The skin microbiome. Nature Rev. Microbiol. 9, 244–253 (2011).

18 Eckburg, P. B. et al. Diversity of the human intestinal microbial flora. Science 308, 1635–1638 (2005).

19 Wiest, R. & Garcia-Tsao, G. Bacterial translocation (BT) in cirrhosis. Hepatology 41, 422–433 (2005).

20 Seki, E. et al. TLR4 enhances TGF-β signaling and hepatic fibrosis. Nature Med. 13, 1324–1332 (2007).

21 Dapito, D. H. et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21, 504–516 (2012).

22 Yoshimoto, S. et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499, 97–101 (2013).

23 Sacksteder, M. R. Occurrence of spontaneous tumors in the germfree F344 rat. J. Natl Cancer Inst. 57, 1371–1373 (1976).

24 Schreiber, H., Nettesheim, P., Lijinsky, W., Richter, C. B. & Walburg, H. E. Jr Induction of lung cancer in germfree, specific-pathogen-free, and infected rats by N-nitrosoheptamethyleneimine: enhancement by respiratory infection. J. Natl Cancer Inst. 49, 1107–1114 (1972).

25 Reddy, B. S. et al. Colon carcinogenesis with azoxymethane and dimethylhydrazine in germ-free rats. Cancer Res. 35, 287–290 (1975).

26 Reddy, B. S. & Watanabe, K. Effect of intestinal microflora on 2,2′-dimethyl-4-aminobiphenyl-induced carcinogenesis in F344 rats. J. Natl Cancer Inst. 61, 1269–1271 (1978).

27 Reddy, B. S., Weisburger, J. H., Narisawa, T. & Wynder, E. L. Colon carcinogenesis in germ-free rats with 1,2-dimethylhydrazine and N-methyl-N′-nitro-N-nitrosoguanidine. Cancer Res. 34, 2368–2372 (1974).

28 Laqueur, G. L., Matsumoto, H. & Yamamoto, R. S. Comparison of the carcinogenicity of methylazoxymethanol-β-D-glucosiduronic acid in conventional and germfree Sprague-Dawley rats. J. Natl Cancer Inst. 67, 1053–1055 (1981).

29 Uronis, J. M. et al. Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS ONE 4, e6026 (2009).

30 Lofgren, J. L. et al. Lack of commensal flora in Helicobacter pylori-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia. Gastroenterology 140, 210–220 (2011).

31 Li, Y. et al. Gut microbiota accelerate tumor growth via c-jun and STAT3 phosphorylation in APCMin/+ mice. Carcinogenesis 33, 1231–1238 (2012).

32 Vannucci, L. et al. Colorectal carcinogenesis in germ-free and conventionally reared rats: different intestinal environments affect the systemic immunity. Int. J. Oncol. 32, 609–617 (2008).

33 Dove, W. F. et al. Intestinal neoplasia in the ApcMin mouse: independence from the microbial and natural killer (beige locus) status. Cancer Res. 57, 812–814 (1997).

34 Chen, G. Y., Shaw, M. H., Redondo, G. & Nunez, G. The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis. Cancer Res. 68, 10060–10067 (2008).

35 Yu, L. X. et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology 52, 1322–1333 (2010).

36 Grivennikov, S. I. et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 491, 254–258 (2012).

37 Klimesova, K. et al. Altered gut microbiota promotes colitis-associated cancer in IL-1 receptor-associated kinase M-deficient mice. Inflamm. Bowel Dis. 19, 1266–1277 (2013).

38 Lee, C. W. et al. Helicobacter pylori eradication prevents progression of gastric cancer in hypergastrinemic INS-GAS mice. Cancer Res. 68, 3540–3548 (2008).

39 Ma, J. L. et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J. Natl Cancer Inst. 104, 488–492 (2012).

40 Wong, B. C. et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 291, 187–194 (2004).

41 Coley, W. B. Treatment of inoperable malignant tumors with the toxins of erysipelas and the Bacillus prodigiosus. Trans. Amer. Surg. Assn 12, 183–212 (1894).

42 Starnes, C. O. Coley's toxins in perspective. Nature 357, 11–12 (1992).

43 Shear, M. J. & Andervont, H. B. Chemical treatment of tumors. III. separation of hemorrhage-producing fraction of B. coli filtrate. Exp. Biol. Med. (Maywood) 34, 323–324 (1936).

44 Pradere, J. P., Dapito, D. H. & Schwabe, R. F. The yin and yang of toll-like receptors in cancer. Oncogene http://dx.doi.org/10.1038/onc.2013.302 (2013).

45 Garaude, J., Kent, A., van Rooijen, N. & Blander, J. M. Simultaneous targeting of Toll- and NOD-like receptors induces effective tumor-specific immune responses. Sci. Transl. Med. 4, 120ra16 (2012).

46 Peek, R. M. Jr & Blaser, M. J. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nature Rev. Cancer 2, 28–37 (2002).

47 Fox, J. G. & Wang, T. C. Inflammation, atrophy, and gastric cancer. J. Clin. Invest. 117, 60–69 (2007).

48 Islami, F. & Kamangar, F. Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev. Res. (Phila) 1, 329–338 (2008).

49 Caygill, C. P., Hill, M. J., Braddick, M. & Sharp, J. C. Cancer mortality in chronic typhoid and paratyphoid carriers. Lancet 343, 83–84 (1994).

50 Welton, J. C., Marr, J. S. & Friedman, S. M. Association between hepatobiliary cancer and typhoid carrier state. Lancet 1, 791–794 (1979).

51 Wotherspoon, A. C. et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342, 575–577 (1993).

52 Lecuit, M. et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N. Engl. J. Med. 350, 239–248 (2004).

53 Senff, N. J. et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 112, 1600–1609 (2008).

54 Ferreri, A. J. et al. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J. Clin. Oncol. 30, 2988–2994 (2012).

55 Grivennikov, S. I. Inflammation and colorectal cancer: colitis-associated neoplasia. Semin. Immunopathol. 35, 229–244 (2012).

56 Ochi, A. et al. MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. J. Exp. Med. 209, 1671–1687 (2012).

57 Michaud, D. S., Joshipura, K., Giovannucci, E. & Fuchs, C. S. A prospective study of periodontal disease and pancreatic cancer in US male health professionals. J. Natl Cancer Inst. 99, 171–175 (2007).

58 Farrell, J. J. et al. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut 61, 582–588 (2012).

59 Pragman, A. A., Kim, H. B., Reilly, C. S., Wendt, C. & Isaacson, R. E. The lung microbiome in moderate and severe chronic obstructive pulmonary disease. PLoS ONE 7, e47305 (2012).

60 Sethi, S. & Murphy, T. F. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N. Engl. J. Med. 359, 2355–2365 (2008).

61 Houghton, A. M. Mechanistic links between COPD and lung cancer. Nature Rev. Cancer 13, 233–245 (2013).

62 Melkamu, T., Qian, X., Upadhyaya, P., O'Sullivan, M. G. & Kassie, F. Lipopolysaccharide enhances mouse lung tumorigenesis: a model for inflammation- driven lung cancer. Vet. Pathol. 50, 895–902 (2013).

63 Swann, J. B. et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc. Natl Acad. Sci. USA 105, 652–656 (2008).

64 Mittal, D. et al. TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J. 29, 2242–2252 (2010).

65 Cataisson, C. et al. IL-1R–MyD88 signaling in keratinocyte transformation and carcinogenesis. J. Exp. Med. 209, 1689–1702 (2012).

66 Backhed, F., Ley, R. E., Sonnenburg, J. L., Peterson, D. A. & Gordon, J. I. Host–bacterial mutualism in the human intestine. Science 307, 1915–1920 (2005).

67 Dethlefsen, L., McFall-Ngai, M. & Relman, D. A. An ecological and evolutionary perspective on human-microbe mutualism and disease. Nature 449, 811–818 (2007).

68 Eloe-Fadrosh, E. A. & Rasko, D. A. The human microbiome: from symbiosis to pathogenesis. Annu. Rev. Med. 64, 145–163 (2013).

69 Salzman, N. H., Underwood, M. A. & Bevins, C. L. Paneth cells, defensins, and the commensal microbiota: a hypothesis on intimate interplay at the intestinal mucosa. Semin. Immunol. 19, 70–83 (2007).

70 Nestle, F. O., Di Meglio, P., Qin, J. Z. & Nickoloff, B. J. Skin immune sentinels in health and disease. Nature Rev. Immunol. 9, 679–691 (2009).

71 Littman, D. R. & Rudensky, A. Y. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 140, 845–858 (2010).

72 Pabst, O. New concepts in the generation and functions of IgA. Nature Rev. Immunol. 12, 821–832 (2012).

73 Ashida, H., Ogawa, M., Kim, M., Mimuro, H. & Sasakawa, C. Bacteria and host interactions in the gut epithelial barrier. Nature Chem. Biol. 8, 36–45 (2011).

74 van Nood, E. et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368, 407–415 (2013).

75 Kamada, N. et al. Regulated virulence controls the ability of a pathogen to compete with the gut microbiota. Science 336, 1325–1329 (2012).

76 Cornforth, D. M. & Foster, K. R. Competition sensing: the social side of bacterial stress responses. Nature Rev. Microbiol. 11, 285–293 (2013).

77 Arthur, J. C. et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338, 120–123 (2012).

78 Couturier-Maillard, A. et al. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J. Clin. Invest. 123, 700–711 (2013).

79 Hu, B. et al. Microbiota-induced activation of epithelial IL-6 signaling links inflammasome-driven inflammation with transmissible cancer. Proc. Natl Acad. Sci. USA 110, 9862–9867 (2013).

80 Khor, B., Gardet, A. & Xavier, R. J. Genetics and pathogenesis of inflammatory bowel disease. Nature 474, 307–317 (2011).

81 Houlston, R. S. et al. Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nature Genet. 42, 973–977 (2010).

82 Peters, U. et al. Identification of genetic susceptibility loci for colorectal tumors in a genome-wide meta-analysis. Gastroenterology 144, 799–807 (2013).

83 Velcich, A. et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 295, 1726–1729 (2002).

84 Irvine, A. D., McLean, W. H. & Leung, D. Y. Filaggrin mutations associated with skin and allergic diseases. N. Engl. J. Med. 365, 1315–1327 (2011).

85 Costello, E. K. et al. Bacterial community variation in human body habitats across space and time. Science 326, 1694–1697 (2009).

86 Caporaso, J. G. et al. Moving pictures of the human microbiome. Genome Biol. 12, R50 (2011).

87 Holmes, E., Li, J. V., Marchesi, J. R. & Nicholson, J. K. Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk. Cell. Metab. 16, 559–564 (2012).

88 Ley, R. E., Turnbaugh, P. J., Klein, S. & Gordon, J. I. Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022–1023 (2006).

89 Ward, J. M. et al. Chronic active hepatitis and associated liver tumors in mice caused by a persistent bacterial infection with a novel Helicobacter species. J. Natl Cancer Inst. 86, 1222–1227 (1994).

90 Erdman, S. E. et al. Nitric oxide and TNF-α trigger colonic inflammation and carcinogenesis in Helicobacter hepaticus-infected, Rag2-deficient mice. Proc. Natl Acad. Sci. USA 106, 1027–1032 (2009).

91 Kim, S. C. et al. Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterology 128, 891–906 (2005).

92 Wu, S. et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nature Med. 15, 1016–1022 (2009).

93 Boulard, O., Kirchberger, S., Royston, D. J., Maloy, K. J. & Powrie, F. M. Identification of a genetic locus controlling bacteria-driven colitis and associated cancer through effects on innate inflammation. J. Exp. Med. 209, 1309–1324 (2012).

94 Rao, V. P. et al. Proinflammatory CD4+ CD45RBhi lymphocytes promote mammary and intestinal carcinogenesis in ApcMin/+ mice. Cancer Res. 66, 57–61 (2006).

95 Garrett, W. S. et al. Colitis-associated colorectal cancer driven by T-bet deficiency in dendritic cells. Cancer Cell 16, 208–219 (2009).

96 Zhang, H. L. et al. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. J. Hepatol 57, 803–812 (2012).

97 Ley, R. E. et al. Obesity alters gut microbial ecology. Proc. Natl Acad. Sci. USA 102, 11070–11075 (2005).

98 Cotillard, A. et al. Dietary intervention impact on gut microbial gene richness. Nature 500, 585–588 (2013).

99 Le Chatelier, E. et al. Richness of human gut microbiome correlates with metabolic markers. Nature 500, 541–546 (2013).

100 Calle, E. E. & Kaaks, R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nature Rev. Cancer 4, 579–591 (2004).

101 Devkota, S. et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10−/− mice. Nature 487, 104–108 (2012).

102 Chen, W., Liu, F., Ling, Z., Tong, X. & Xiang, C. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS ONE 7, e39743 (2012).

103 Sanapareddy, N. et al. Increased rectal microbial richness is associated with the presence of colorectal adenomas in humans. ISME J. 6, 1858–1868 (2012).

104 Sobhani, I. et al. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS ONE 6, e16393 (2011).

105 Wang, T. et al. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J. 6, 320–329 (2011).

106 Kostic, A. D. et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 22, 292–298 (2012).

107 Kostic, A. D. et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14, 207–215 (2013).

108 McCoy, A. N. et al. Fusobacterium is associated with colorectal adenomas. PLoS ONE 8, e53653 (2013).

109 Rubinstein, M. R. et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 14, 195–206 (2013).

110 Allen-Vercoe, E., Strauss, J. & Chadee, K. Fusobacterium nucleatum: an emerging gut pathogen? Gut Microbes 2, 294–298 (2011).

111 Stecher, B. et al. Gut inflammation can boost horizontal gene transfer between pathogenic and commensal Enterobacteriaceae. Proc. Natl Acad. Sci. USA 109, 1269–1274 (2012).

112 Elinav, E., Strowig, T., Henao-Mejia, J. & Flavell, R. A. Regulation of the antimicrobial response by NLR proteins. Immunity 34, 665–679 (2011).

113 Winter, S. E. et al. Host-derived nitrate boosts growth of E. coli in the inflamed gut. Science 339, 708–711 (2013).

114 Lupp, C. et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2, 204 (2007).

115 Morgan, X. C. et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 13, R79 (2012).

116 Vijay-Kumar, M. et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 328, 228–231 (2012).

117 Patwa, L. G. et al. Chronic intestinal inflammation induces stress-response genes in commensal Escherichia coli. Gastroenterology 141, 1842–1851 (2011).

118 Hajishengallis, G., Darveau, R. P. & Curtis, M. A. The keystone-pathogen hypothesis. Nature Rev. Microbiol. 10, 717–725 (2012).

119 Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).

120 Moresco, E. M., LaVine, D. & Beutler, B. Toll-like receptors. Curr. Biol. 21, R488–R493 (2011).

121 Fukata, M. et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 133, 1869–1881 (2007).

122 Fukata, M. et al. Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. Inflamm Bowel Dis. 17, 1464–1473 (2011).

123 Tye, H. et al. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell 22, 466–478 (2012).

124 Ngo, V. N. et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 470, 115–119 (2011).

125 Brandl, K. et al. MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating specific EGF receptor ligands. Proc. Natl Acad. Sci. USA 107, 19967–19972 (2010).

126 Neufert, C. et al. Tumor fibroblast–derived epiregulin promotes growth of colitis-associated neoplasms through ERK. J. Clin. Invest. 123, 1428–1443 (2013).

127 Naugler, W. E. et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317, 121–124 (2007).

128 Rakoff-Nahoum, S. & Medzhitov, R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 317, 124–127 (2007).

129 Lee, S. H. et al. ERK activation drives intestinal tumorigenesis in Apcmin/+ mice. Nature Med. 16, 665–670 (2010).

130 Kennedy, C. L. et al. Differential role of MyD88 and Mal/TIRAP in TLR2-mediated gastric tumourigenesis. Oncogene http://dx.doi.org/10.1038/onc.2013.205 (2013).

131 Salcedo, R. et al. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J. Exp. Med. 207, 1625–1636 (2010).

132 Cho, J. H. The genetics and immunopathogenesis of inflammatory bowel disease. Nature Rev. Immunol. 8, 458–466 (2008).

133 Kobayashi, K. S. et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307, 731–734 (2005).

134 Petnicki-Ocwieja, T. et al. Nod2 is required for the regulation of commensal microbiota in the intestine. Proc. Natl Acad. Sci. USA 106, 15813–15818 (2009).

135 Rehman, A. et al. Nod2 is essential for temporal development of intestinal microbial communities. Gut 60, 1354–1362 (2011).

136 McGovern, D. P. et al. Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. Hum. Mol. Genet. 14, 1245–1250 (2005).

137 Allen, I. C. et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J. Exp. Med. 207, 1045–1056 (2010).

138 Allen, I. C. et al. NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-κB signaling. Immunity 36, 742–754 (2012).

139 Hu, B. et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc. Natl Acad. Sci. USA 107, 21635–21640 (2010).

140 Travaglione, S., Fabbri, A. & Fiorentini, C. The Rho-activating CNF1 toxin from pathogenic E. coli: a risk factor for human cancer development? Infect. Agent Cancer 3, 4 (2008).

141 Nesic, D., Hsu, Y. & Stebbins, C. E. Assembly and function of a bacterial genotoxin. Nature 429, 429–433 (2004).

142 Cuevas-Ramos, G. et al. Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc. Natl Acad. Sci. USA 107, 11537–11542 (2010).

143 Smith, J. L. & Bayles, D. O. The contribution of cytolethal distending toxin to bacterial pathogenesis. Crit. Rev. Microbiol. 32, 227–248 (2006).

144 Elwell, C. A. & Dreyfus, L. A. DNase I homologous residues in CdtB are critical for cytolethal distending toxin-mediated cell cycle arrest. Mol. Microbiol. 37, 952–963 (2000).

145 Fox, J. G. et al. Gastroenteritis in NF-κB-deficient mice is produced with wild-type Camplyobacter jejuni but not with C. jejuni lacking cytolethal distending toxin despite persistent colonization with both strains. Infect. Immun. 72, 1116–1125 (2004).

146 Shen, Z. et al. Cytolethal distending toxin promotes Helicobacter cinaedi-associated typhlocolitis in interleukin-10-deficient mice. Infect. Immun. 77, 2508–2516 (2009).

147 Nougayrede, J. P. et al. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science 313, 848–851 (2006).

148 Buc, E. et al. High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer. PLoS ONE 8, e56964 (2013).

149 Garrett, W. S. et al. Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis. Cell Host Microbe 8, 292–300 (2010).

150 Putze, J. et al. Genetic structure and distribution of the colibactin genomic island among members of the family Enterobacteriaceae. Infect. Immun. 77, 4696–4703 (2009).

151 Carbonero, F., Benefiel, A. C., Alizadeh-Ghamsari, A. H. & Gaskins, H. R. Microbial pathways in colonic sulfur metabolism and links with health and disease. Front. Physiol. 3, 448 (2012).

152 Huycke, M. M. & Gaskins, H. R. Commensal bacteria, redox stress, and colorectal cancer: mechanisms and models. Exp. Biol. Med. (Maywood) 229, 586–597 (2004).

153 Wang, X. & Huycke, M. M. Extracellular superoxide production by Enterococcus faecalis promotes chromosomal instability in mammalian cells. Gastroenterology 132, 551–561 (2007).

154 Wang, X. et al. 4-hydroxy-2-nonenal mediates genotoxicity and bystander effects caused by Enterococcus faecalis-infected macrophages. Gastroenterology 142, 543–551 (2012).

155 Balish, E. & Warner, T. Enterococcus faecalis induces inflammatory bowel disease in interleukin-10 knockout mice. Am. J. Pathol. 160, 2253–2257 (2002).

156 Castellarin, M. et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 22, 299–306 (2012).

157 Attene-Ramos, M. S., Wagner, E. D., Plewa, M. J. & Gaskins, H. R. Evidence that hydrogen sulfide is a genotoxic agent. Mol. Cancer Res. 4, 9–14 (2006).

158 Ohnishi, N. et al. Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc. Natl Acad. Sci. USA 105, 1003–1008 (2008).

159 Han, Y. W. et al. Identification and characterization of a novel adhesin unique to oral fusobacteria. J. Bacteriol. 187, 5330–5340 (2005).

160 Philipp, B. Bacterial degradation of bile salts. Appl. Microbiol. Biotechnol. 89, 903–915 (2011).

161 Bernstein, C. et al. Carcinogenicity of deoxycholate, a secondary bile acid. Arch. Toxicol. 85, 863–871 (2011).

162 Quante, M. et al. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell 21, 36–51 (2012).

163 Nyangale, E. P., Mottram, D. S. & Gibson, G. R. Gut microbial activity, implications for health and disease: the potential role of metabolite analysis. J. Proteome Res. 11, 5573–5585 (2012).

164 Windey, K., De Preter, V. & Verbeke, K. Relevance of protein fermentation to gut health. Mol. Nutr. Food Res. 56, 184–196 (2012).

165 Hawksworth, G. M. & Hill, M. J. Bacteria and the N-nitrosation of secondary amines. Br. J. Cancer 25, 520–526 (1971).

166 Alam, B. S., Saporoschetz, I. B. & Epstein, S. S. Synthesis of nitrosopiperidine from nitrate and piperidine in the gastro-intestinal tract of the rat. Nature 232, 199–200 (1971).

167 Russell, W. R. et al. High-protein, reduced-carbohydrate weight-loss diets promote metabolite profiles likely to be detrimental to colonic health. Am. J. Clin. Nutr. 93, 1062–1072 (2011).

168 Bindels, L. B. et al. Gut microbiota-derived propionate reduces cancer cell proliferation in the liver. Br. J. Cancer 107, 1337–1344 (2012).

169 Donohoe, D. R. et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell. Metab. 13, 517–526 (2011).

170 Hu, S. et al. The microbe-derived short chain fatty acid butyrate targets miRNA-dependent p21 gene expression in human colon cancer. PLoS ONE 6, e16221 (2011).

171 Maslowski, K. M. et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461, 1282–1286 (2009).

172 Eberhardt, M. V., Lee, C. Y. & Liu, R. H. Antioxidant activity of fresh apples. Nature 405, 903–904 (2000).

173 DeWeerdt, S. Food: The omnivore's labyrinth. Nature 471, S22–S24 (2011).

174 Yang, C. S., Wang, X., Lu, G. & Picinich, S. C. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nature Rev. Cancer 9, 429–439 (2009).

175 van Duynhoven, J. et al. Metabolic fate of polyphenols in the human superorganism. Proc. Natl Acad. Sci. USA 108 (Suppl. 1), 4531–4538 (2011).

176 Fardet, A. et al. Metabolomics provide new insight on the metabolism of dietary phytochemicals in rats. J. Nutr. 138, 1282–1287 (2008).

177 Dutton, R. J. & Turnbaugh, P. J. Taking a metagenomic view of human nutrition. Curr. Opin. Clin. Nutr. Metab. Care 15, 448–454 (2012).

178 Chang, M. C. & Keasling, J. D. Production of isoprenoid pharmaceuticals by engineered microbes. Nature Chem. Biol. 2, 674–681 (2006).

179 Mabrok, H. B. et al. Lignan transformation by gut bacteria lowers tumor burden in a gnotobiotic rat model of breast cancer. Carcinogenesis 33, 203–208 (2012).

180 Adlercreutz, H. Phyto-oestrogens and cancer. Lancet Oncol. 3, 364–373 (2002).

181 Haiser, H. J. & Turnbaugh, P. J. Is it time for a metagenomic basis of therapeutics? Science 336, 1253–1255 (2012).

182 Wallace, B. D. et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330, 831–835 (2010).

183 Kassie, F. et al. Intestinal microflora plays a crucial role in the genotoxicity of the cooked food mutagen 2-amino-3-methylimidazo [4,5-f]quinoline. Carcinogenesis 22, 1721–1725 (2001).

184 Hirayama, K. et al. Effects of human intestinal flora on mutagenicity of and DNA adduct formation from food and environmental mutagens. Carcinogenesis 21, 2105–2111 (2000).

185 Vanhaecke, L. et al. Intestinal bacteria metabolize the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine following consumption of a single cooked chicken meal in humans. Food Chem. Toxicol. 46, 140–148 (2008).

186 Sharp, J. O., Wood, T. K. & Alvarez-Cohen, L. Aerobic biodegradation of N-nitrosodimethylamine (NDMA) by axenic bacterial strains. Biotechnol. Bioeng. 89, 608–618 (2005).

187 Seitz, H. K. & Stickel, F. Molecular mechanisms of alcohol-mediated carcinogenesis. Nature Rev. Cancer 7, 599–612 (2007).

188 Seitz, H. K. et al. Possible role of acetaldehyde in ethanol-related rectal cocarcinogenesis in the rat. Gastroenterology 98, 406–413 (1990).

189 Plottel, C. S. & Blaser, M. J. Microbiome and malignancy. Cell Host Microbe 10, 324–335 (2011).

190 Markle, J. G. et al. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science 339, 1084–1088 (2013).

191 Chung, H. et al. Gut immune maturation depends on colonization with a host-specific microbiota. Cell 149, 1578–1593 (2012).

192 Singh, S., Eldin, C., Kowalczewska, M. & Raoult, D. Axenic culture of fastidious and intracellular bacteria. Trends Microbiol. 21, 92–99 (2013).

193 Bull, A. T. The renaissance of continuous culture in the post-genomics age. J. Ind. Microbiol. Biotechnol. 37, 993–1021 (2010).

194 Arthur, J. C. & Jobin, C. The complex interplay between inflammation, the microbiota and colorectal cancer. Gut Microbes 4, 253–258 (2013).

195 Hooper, L. V., Littman, D. R. & Macpherson, A. J. Interactions between the microbiota and the immune system. Science 336, 1268–1273 (2012).

196 Ubeda, C. et al. Familial transmission rather than defective innate immunity shapes the distinct intestinal microbiota of TLR-deficient mice. J. Exp. Med. 209, 1445–1456 (2012).

197 Shanahan, M. T. et al. Mouse Paneth cell antimicrobial function is independent of Nod2. Gut http://dx.doi.org/10.1136/gutjnl-2012-304190 (2013).

198 Robertson, S. J. et al. Nod1 and Nod2 signaling does not alter the composition of intestinal bacterial communities at homeostasis. Gut Microbes 4, 222–231 (2013).

199 McCafferty, J. et al. Stochastic changes over time and not founder effects drive cage effects in microbial community assembly in a mouse model. ISME J. http://dx.doi.org/10.1038/ismej.2013.106 (2013).